Genflow Biosciences PLC
GENF
Company Profile
Business description
Genflow Biosciences PLC is a preclinical biotechnology company focused on developing innovative biological interventions aimed at tackling the effects of aging, potentially slowing or halting the aging process and reducing the incidence of age-related diseases and thereby increasing life span. The company is also focused on longevity and the development of therapies to counteract the effects of aging and diseases associated with age.
Contact
6 Heddon Street
LondonW1B 4BT
GBRT: +44 2081425409
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
Stocks News & Analysis
stocks
What next for Tesla as 2024 deliveries disappoint?
Tesla shares started the year on a sour note. We think they continue to price in ambitious growth going forward.
stocks
Best and worst performing ASX sectors of 2024
Exploring the ASX sectors that moved the market this year.
stocks
2 ASX companies with the traits of a long-term winner
Two companies that show promising signs of handsomely rewarding shareholders.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,511.90 | 46.90 | 0.55% |
| CAC 40 | 7,282.22 | 111.54 | -1.51% |
| DAX 40 | 19,906.08 | 118.58 | -0.59% |
| Dow JONES (US) | 42,732.13 | 339.86 | 0.80% |
| FTSE 100 | 8,223.98 | 36.11 | -0.44% |
| HKSE | 19,760.27 | 136.95 | 0.70% |
| NASDAQ | 19,621.68 | 340.88 | 1.77% |
| Nikkei 225 | 39,894.54 | 386.62 | -0.96% |
| NZX 50 Index | 13,067.83 | 42.91 | -0.33% |
| S&P 500 | 5,942.47 | 73.92 | 1.26% |
| S&P/ASX 200 | 8,250.50 | 49.30 | 0.60% |
| SSE Composite Index | 3,211.43 | 51.13 | -1.57% |